Watchlist Price Alert

Trevi Therapeutics Inc. (TRVI)

NASDAQ: TRVI · Real-Time Price · USD

6.77

0.19 (2.89%)

At close: Jun 05, 2025, 3:59 PM

6.98

3.12%

After-hours: Jun 05, 2025, 07:47 PM EDT

2.89% (1D)

Bid	6.72
Market Cap	688.81M
Revenue (ttm)	n/a
Net Income (ttm)	-47.35M
EPS (ttm)	-0.45
PE Ratio (ttm)	-15.04
Forward PE	-11.76
Analyst	Buy

Ask	6.98
Volume	2,354,999
Avg. Volume (20D)	2,630,639
Open	6.46
Previous Close	6.58
Day's Range	6.35 - 6.90
52-Week Range	2.30 - 7.48
Beta	0.53

About TRVI

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TRVI

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for TRVI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 days ago

-5.85%

Trevi Therapeutics shares are trading lower after ... Unlock content with Pro Subscription

4 days ago

-2.92%

TRVI stock has given up its prior gain. Trevi Therapeutics shares were trading higher after the company announced positive topline results from its Phase 2b CORAL trial of Haduvio.

News

4 days ago · benzinga.com

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

Trevi Therapeutics, Inc. TRVI revealed topline results on Monday from its Phase 2b CORAL trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) (N=165).

3 weeks ago · zacks.com

Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?

The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 195.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am...

3 weeks ago · seekingalpha.com

Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Jennifer Good - Co-Founder, President and Chief Executive Officer Lisa Delfini - Ch...

2 months ago · seekingalpha.com

Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Jennifer Good - Co-Founder, President and Chief Executive Officer Lisa Delfini -...

2 months ago · benzinga.com

Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps

On Monday, Trevi Therapeutics, Inc. TRVI reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) for the treatment of patients with refractory chronic cough (N=66).